Last reviewed · How we verify
NCT06156202
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
NA trial testing Comprehensive Rehabilitation in Post-Acute COVID-19 in 125 participants. Completed in 30 November 2025.
30 November 2025
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 125 |
| Start date | 15 November 2023 |
| Primary completion | 30 November 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Comprehensive Rehabilitation
- Augmented Usual Care
Conditions studied
- Post-Acute COVID-19 — all drugs for Post-Acute COVID-19 →
- Post-Acute COVID-19 Syndrome — all drugs for Post-Acute COVID-19 Syndrome →
- Post-Acute COVID-19 Infection — all drugs for Post-Acute COVID-19 Infection →
- Long COVID — all drugs for Long COVID →
Sponsor
University of Pennsylvania
Who can join
Eligibility, any sex, with Post-Acute COVID-19 or Post-Acute COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
About 10-20% of persons who contract SARS CoV-2 will experience persistent post-acute sequelae of SARSCoV-2 infection (referred here as PASC). While treatments offered at emerging outpatient COVID recovery clinics are being informed by previous similar diseases, the need is great for a better understanding of the unique needs of this growing population and for tested, efficacious rehabilitation programs to address them. We provide both here.The targeted six-week program will be comprised of a core set of therapies, including individually titrated stretching and flexibility, strengthening of accessory breathing muscles and diaphragm, resistance and aerobic conditioning, and vestibular rehabilitation, supplemented by neuropsychological and cognitive remediation tailored to patients' needs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Rationale, Evidence, and Adaptations to Pulmonary Rehabilitation for Chronic Respiratory Diseases Other Than COPD.
Evans RA. · · 2024 · cited 3× · PMID 38806225 · DOI 10.4187/respcare.12089 -
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program to Improve the Functioning of Persons Suffering from Post-acute Sequelae of SARS-CoV-2 infection (PASC): A Randomized Controlled Trial
Abramoff MB, Dillingham MT, Rybicki MMA, Shofer F, et al · · 2025 · DOI 10.21203/rs.3.rs-7375832/v1
Verify or expand the search:
- PubMed search for NCT06156202
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post-Acute COVID-19
Currently open trials in the same condition.
- NCT07140094 — Long-Covid-19 Alleviation Through Learning Mindfulness Study · NA · recruiting
- NCT06161688 — Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID · Phase 2 · active not recruiting
- NCT05877508 — Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19) · Phase 2 · active not recruiting
- NCT05866952 — Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection · recruiting
- NCT05745805 — Cohort Follow-up of Epidemic and Neuroimaging for Patients During the 1st Wave of the COVID-19 in China · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06156202 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06156202.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing